Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas

Background: We have previously shown that 3-Deazaneplanocin A (DZNep) induces apoptosis in chondrosarcomas. Herein, we tested whether the combination of this epigenetic drug to a standard anticancer therapy may enhance the response to each drug in these bone tumors. Methods: Two chondrosarcoma cell...

Full description

Bibliographic Details
Main Authors: Eva Lhuissier, Juliette Aury-Landas, Marion Lenté, Karim Boumediene, Catherine Baugé
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
apoptosis
bone tumors
chondrosarcoma
cell death
xenograft
cisplatin
Online Access:https://www.mdpi.com/2072-6694/13/18/4648

Similar Items

Similar Items